28 related articles for article (PubMed ID: 9414030)
1. Roflupram protects against rotenone-induced neurotoxicity and facilitates α-synuclein degradation in Parkinson's disease models.
Dong WL; Zhong JH; Chen YQ; Xie JF; Qin YY; Xu JP; Cai NB; Li MF; Liu L; Wang HT
Acta Pharmacol Sin; 2021 Dec; 42(12):1991-2003. PubMed ID: 34531546
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.
Cardinale A; Fusco FR
CNS Neurosci Ther; 2018 Apr; 24(4):319-328. PubMed ID: 29500937
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP
Zhong J; Yu H; Huang C; Zhong Q; Chen Y; Xie J; Zhou Z; Xu J; Wang H
Redox Biol; 2018 Jun; 16():47-58. PubMed ID: 29475134
[TBL] [Abstract][Full Text] [Related]
4. The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.
Liu X; Hao PD; Yang MF; Sun JY; Mao LL; Fan CD; Zhang ZY; Li DW; Yang XY; Sun BL; Zhang HT
Psychopharmacology (Berl); 2017 Aug; 234(16):2409-2419. PubMed ID: 28477089
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.
Knott EP; Assi M; Rao SN; Ghosh M; Pearse DD
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28338622
[TBL] [Abstract][Full Text] [Related]
6. Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?
Nthenge-Ngumbau DN; Mohanakumar KP
Mol Neurobiol; 2018 Jan; 55(1):822-834. PubMed ID: 28062949
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications.
Heckman PRA; van Duinen MA; Bollen EPP; Nishi A; Wennogle LP; Blokland A; Prickaerts J
Int J Neuropsychopharmacol; 2016 Apr; 19(10):. PubMed ID: 27037577
[TBL] [Abstract][Full Text] [Related]
8. PDE4 as a target for cognition enhancement.
Richter W; Menniti FS; Zhang HT; Conti M
Expert Opin Ther Targets; 2013 Sep; 17(9):1011-27. PubMed ID: 23883342
[TBL] [Abstract][Full Text] [Related]
9. Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and related psychostimulants: mechanisms and mediators.
Vanattou-Saïfoudine N; McNamara R; Harkin A
Br J Pharmacol; 2012 Nov; 167(5):946-59. PubMed ID: 22671762
[TBL] [Abstract][Full Text] [Related]
10. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum.
Nishi A; Kuroiwa M; Miller DB; O'Callaghan JP; Bateup HS; Shuto T; Sotogaku N; Fukuda T; Heintz N; Greengard P; Snyder GL
J Neurosci; 2008 Oct; 28(42):10460-71. PubMed ID: 18923023
[TBL] [Abstract][Full Text] [Related]
11. Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases.
O'Donnell JM; Frith S
Pharmacol Biochem Behav; 1999 May; 63(1):185-92. PubMed ID: 10340540
[TBL] [Abstract][Full Text] [Related]
12. Modulation of cellular responses by hormones: role of cAMP specific, rolipram-sensitive phosphodiesterases.
Sette C; Vicini E; Conti M
Mol Cell Endocrinol; 1994 Apr; 100(1-2):75-9. PubMed ID: 8056162
[No Abstract] [Full Text] [Related]
13. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission.
Nishi A; Snyder GL
J Pharmacol Sci; 2010; 114(1):6-16. PubMed ID: 20716858
[TBL] [Abstract][Full Text] [Related]
14. Rolipram, a phosphodiesterase-4-selective inhibitor, promotes the survival of cultured rat dopaminergic neurons.
Yamashita N; Hayashi A; Baba J; Sawa A
Jpn J Pharmacol; 1997 Oct; 75(2):155-9. PubMed ID: 9414030
[TBL] [Abstract][Full Text] [Related]
15. Rolipram, a selective inhibitor of phosphodiesterase type 4, pronouncedly enhanced the forskolin-induced promotion of dopamine biosynthesis in primary cultured rat mesencephalic neurons.
Yamashita N; Miyashiro M; Baba J; Sawa A
Jpn J Pharmacol; 1997 Sep; 75(1):91-5. PubMed ID: 9334890
[TBL] [Abstract][Full Text] [Related]
16. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.
Michie AM; Lobban M; Müller T; Harnett MM; Houslay MD
Cell Signal; 1996 Feb; 8(2):97-110. PubMed ID: 8730511
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
